Filing Analysis
Impact BioMedical Inc. has amended its merger agreement with Dr Ashleys Limited, extending the transaction deadline to July 1, 2026, and establishing share-based compensation for its CEO and major shareholder DSS, Inc. The amendment also introduces a requirement for Impact to potentially co-sign loan agreements for the target company prior to the merger's closing.
🚩 Red Flags
- Related-party compensation: The CEO is receiving 22,000 shares directly linked to the merger agreement.
- Affiliate benefits: Major shareholder DSS, Inc. is receiving 128,000 shares for 'funding obligations,' suggesting the company is reliant on this affiliate for transaction liquidity.
- Pre-closing liabilities: The company may be forced to co-sign loans for the target entity before the merger is even finalized.
- Timeline extension: Moving the end date by three months indicates potential delays in regulatory or financial closing conditions.
📋 Key Facts
- The merger 'End Date' was extended from March 31, 2026, to July 1, 2026.
- CEO Frank D. Heuszel is slated to receive 22,000 PubCo ordinary shares as compensation.
- Major shareholder DSS, Inc. will receive up to 128,000 PubCo shares (53,000 in a first batch and 75,000 in a second batch) in exchange for funding and hold harmless obligations.
- Supporting stockholders currently hold 92,980,843 shares, representing approximately 88.87% of the company on a fully diluted basis.
- Impact BioMedical may be required to co-sign loan agreements requested by the target (Dr Ashleys) or PubCo prior to the merger's effective time, subject to board approval.
- The total 'Company Share Consideration' is defined as 169,560,000 PubCo ordinary shares, representing 94.20% of the post-closing entity.
Impact Biomedical Inc. held its 2025 annual meeting of stockholders on November 5, 2025. The results included the election of eight directors and the ratification of Grassi & Co. as the independent auditor.
📋 Key Facts
- Annual Meeting held on November 5, 2025.
- Quorum reached with 64,328,010 shares (88.50% of aggregate shares outstanding) represented.
- Eight directors elected: Frank D. Heuszel, Elise Brownell, Melissa Sims, Castel Hibbert, David Keene, Christian Zimmerman, Jason Grady, and Chan Heng Fai Ambrose.
- Grassi & Co. Certified Public Accountants, P.C. ratified as independent auditor for fiscal year ending Dec 31, 2025.
- Executive officer compensation approved on an advisory basis.
DSS BioHealth Security, Inc. has exercised its option to convert 60,496,041 shares of Series A Convertible Preferred Stock into common stock. This event results in a significant increase in the total number of outstanding common shares.
🚩 Red Flags
- Significant potential dilution for existing common shareholders due to the issuance of over 60 million new shares.
- The conversion is an 'Optional Conversion' by a large holder, which often precedes selling pressure in micro-cap stocks.
📋 Key Facts
- Conversion date: October 24, 2025
- Converting entity: DSS BioHealth Security, Inc.
- Number of shares to be issued: 60,496,041 shares of Common Stock
- Original instrument: Series A Convertible Preferred Stock (dated Oct 30, 2023)
Impact BioMedical Inc. entered into a Debt Conversion Agreement with DSS, Inc. to settle an outstanding revolving promissory note originally issued on March 31, 2023. The settlement involves the issuance of approximately 31.9 million shares of common stock to satisfy all debt obligations and additional support provided by the lender.
🚩 Red Flags
- Significant dilution: The issuance of nearly 32 million shares to settle debt represents massive potential dilution for existing shareholders.
- Debt-for-equity swap: Often indicates a liquidity crisis where the company lacks sufficient cash to service its obligations.
- Complexity of settlement: Includes 'additional financial or operations support, credit, or services' owed between June 21, 2025, and closing, making the total debt amount variable/opaque.
📋 Key Facts
- Date of agreement: July 21, 2025
- Lender: DSS, Inc.
- Debt being settled: Original $12,000,000 revolving promissory note (plus interest and additional support/services)
- Settlement mechanism: Issuance of 31,939,778 shares of freely tradeable common stock
- Scope of settlement: Full and final satisfaction of the Original Note and all amounts owed as of the closing date.
Impact BioMedical Inc. has entered into a definitive merger and share exchange agreement with Dr Ashleys Limited (a Cayman Islands company) to facilitate a reverse takeover/merger. The transaction involves a significant restructuring, including a mandatory reverse stock split of Impact's common stock prior to the effective time.
🚩 Red Flags
- Mandatory reverse stock split (NYSE Reverse Split) required as part of the transaction structure.
- Significant dilution for existing Impact shareholders (receiving only 4.80% of the combined entity).
- Change in control: The current board and officers will resign, and management will be designated by Dr Ashleys Cayman.
- Complex multi-party structure involving a Cayman Islands 'PubCo' and multiple subsidiaries.
📋 Key Facts
- Merger Agreement signed on June 21, 2025.
- Impact shareholders will receive PubCo Ordinary Shares representing 4.80% of total issued and outstanding shares at closing.
- Dr Ashleys Cayman (the target/merging entity) will receive 94.20% of the PubCo Ordinary Shares.
- A mandatory reverse stock split ('NYSE Reverse Split') is required for Impact's common stock prior to the merger effective time.
- The transaction requires NYSE approval for the listing and share issuance.
- Impact must have net cash of at least $10,000 and zero net debt at closing.
- 86.81% of Impact's shares are already committed via a Voting Agreement to support the merger.
Impact BioMedical Inc. announced that the creditor, DSS, Inc., has withdrawn from a previously reported Debt Conversion Agreement dated March 24, 2025. Consequently, no shares will be issued to settle the outstanding $13,176,477.03 promissory note at this time.
🚩 Red Flags
- Significant debt burden: The company carries a massive $13.17M promissory note which represents a major liability for a micro-cap entity.
- Failed debt restructuring: The creditor's withdrawal from the conversion agreement suggests market volatility or unfavorable terms, leaving the debt on the balance sheet.
- Potential liquidity/solvency risk: Failure to convert significant debt into equity often precedes distressed financing or insolvency if cash flow is insufficient to service the note.
📋 Key Facts
- The company had an outstanding Promissory Note with DSS, Inc. dated September 16, 2024.
- The principal balance of the note as of March 24, 2025, was $13,176,477.03.
- DSS, Inc. has withdrawn from the Debt Conversion Agreement due to 'current market conditions'.
- No shares were issued in connection with this specific debt conversion attempt.
Impact BioMedical Inc. has entered into a debt conversion agreement to settle a significant portion of its outstanding promissory note with DSS, Inc. via the issuance of common stock.
🚩 Red Flags
- Significant dilution risk: Issuance of over 2.4 million shares to settle debt.
- High leverage: The company is settling a massive portion of its debt through equity rather than cash, indicating potential liquidity constraints.
- Debt-to-Equity conversion pattern: Frequent use of debt conversion can lead to 'death spiral' mechanics if the stock price fluctuates significantly.
📋 Key Facts
- Date of Agreement: March 24, 2025
- Total Promissory Note Principal Balance (as of March 24, 2025): $13,176,477.03
- Settlement Amount: $8,697,142.80
- Shares to be Issued: 2,415,873 shares of common stock
- Conversion Price: $3.60 per share (equal to the closing market price on March 24, 2025)
- Remaining Debt Balance (approximate): $4,479,334.23
Impact Biomedical Inc. announced the appointment of Mr. Chan Heng Fai Ambrose to its Board of Directors, effective March 11, 2025.
📋 Key Facts
- Appointment date: March 11, 2025.
- New Director: Mr. Chan Heng Fai Ambrose.
- Mr. Chan has over 45 years of experience in financial and equity investment industries.
- Mr. Chan holds/has held leadership roles at several public companies including Alset International Limited (SGX), Hapi Metaverse Inc. (SEC filer), DSS, Inc. (NYSE), LiquidValue Development Inc. (SEC filer), and Sharing Services Global Corporation (OTC Pink).
- The company confirmed no family relationship exists between Mr. Chan and any current director or executive officer.
- No related-party transactions were disclosed in connection with this appointment.
Impact Biomedical Inc. filed an 8-K to provide investor information via a slide package prepared by CEO Frank D. Heuszel. The filing is for Regulation FD purposes and includes an updated investor presentation dated January 2025.
📋 Key Facts
- CEO Frank D. Heuszel provided certain investor information on January 29, 2025.
- The company furnished a slide package (Exhibit 99.1) as part of the disclosure.
- Information in the presentation is current as of January 29, 2025.
Impact Biomedical Inc. filed an 8-K to provide investor information via a slide package presented by COO Mark Suseck. The filing is for Regulation FD purposes and contains no material changes to operations, finances, or corporate structure.
📋 Key Facts
- The company provided investor information through a presentation prepared by COO Mark Suseck.
- The presentation is dated as of November 4, 2024.
- Information in the exhibit is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Impact BioMedical Inc. entered into a new three-year employment agreement with its current CEO, Chairman, and President, Frank D. Heuszel, effective October 3, 2024.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Term of agreement: October 3, 2024, to October 3, 2027.
- Base Salary: $200,000 in Year 1; $250,000 in Years 2 and 3.
- Mandatory Bonus: $150,000 in Year 1; $100,000 in Years 2 and 3 (subject to continuous employment).
- Equity Grant: Option to purchase 300,000 shares of common stock at an exercise price of $3.00 per share.
- The option price is equal to the fair market value as of the grant date.
Impact Biomedical Inc. has completed an initial public offering (IPO) of 1,500,000 common shares at $3.00 per share, resulting in net proceeds of approximately $3.76 million. The company began trading on the NYSE American under the ticker 'IBO' on September 16, 2024.
🚩 Red Flags
- Warrant issuance to the Representative (5% coverage) can lead to future dilution and potential downward pressure on the stock price upon exercise.
📋 Key Facts
- Offered 1,500,000 shares of common stock at a public offering price of $3.00 per share.
- Total net proceeds to the Company are approximately $3,764,500 after discounts and expenses.
- The offering was conducted via an underwriting agreement with Revere Securities, LLC.
- Issued warrants to the Representative equal to 5% of the shares issued in the offering, exercisable at 125% of the public offering price ($3.75).
- Lock-up agreements were established for Directors, Officers, and certain affiliates for a period of six months from the effective date.
- The company's common stock is listed on the NYSE American under the symbol 'IBO'.
Impact Biomedical Inc. announced a change in its Board of Directors effective June 6, 2024. The company reported the resignation of Heng Fai Ambrose Chan and the appointment of Jason T. Grady to the Board.
📋 Key Facts
- Heng Fai Ambrose Chan resigned from the Board of Directors effective June 6, 2024.
- The Company stated Chan's resignation does not reflect any disagreement regarding operations, policies, or practices.
- Jason T. Grady was appointed to the Board of Directors effective June 6, 2024.
- Mr. Grady brings extensive experience in capital markets, M&A, and corporate restructuring from his roles at DSS, Inc. and Premier Packaging Corporation.
- The filing notes no family relationships or related-party transactions involving Mr. Grady.
Impact BioMedical Inc. has amended a revolving promissory note with its majority shareholder, DSS, Inc., extending the maturity date to September 30, 2030. The amendment increases the funded principal balance to $12,859,328.60 and establishes a repayment schedule involving monthly interest payments followed by principal and interest installments.
🚩 Red Flags
- Related-party transaction: The lender (DSS, Inc.) is the majority shareholder of Impact BioMedical.
- High leverage/Debt burden: Total debt balance exceeds $12.8M with a blanket first lien on all assets and intellectual property.
- Repayment structure: Significant monthly cash outflows required starting February 2024 to cover accrued interest.
📋 Key Facts
- Amendment effective January 18, 2024, with DSS, Inc. (majority shareholder) as the lender.
- Funded principal balance increased to $12,859,328.60.
- Maturity date extended from original terms to September 30, 2030.
- Interest rate is WSJ Prime + 0.50% floating daily (initial rate of 9%).
- Repayment includes monthly interest through January 2026, followed by $126,380.80 monthly payments through August 2030.
- The note is secured by a blanket first lien on all company assets, including licenses and patents.